Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/6/2026

1. KRG
2. SPY
3. ALAR
4. EXC
5. SKA-B
6. PBA
7. CCH:LN
8. META
9. BAJAJHFL:I
10. CCHGY

Go back to Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma

Exelixis (EXEL) PT Raised to $35 at SunTrust Robinson Humphrey

October 16, 2017 11:16 AM EDT

SunTrust Robinson Humphrey raised its price target on Exelixis (NASDAQ: EXEL) to $35.00 (from $33.00) while maintaining a Buy rating.

... More